Details of Drug-Drug Interaction
| Drug General Information (ID: DDIJ1ZYT53) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Drug Name | Colesevelam | Drug Info | Venetoclax | Drug Info | |||||
| Drug Type | Small molecule | Small molecule | |||||||
| Therapeutic Class | Bile Acid Sequestrants | Antineoplastics | |||||||
| Structure | |||||||||
| Mechanism of Colesevelam-Venetoclax Interaction (Severity Level: Moderate) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Complex formation Click to Show/Hide Mechanism Graph | |||||||||
![]() |
|||||||||
| Drug Name | Colesevelam | Venetoclax | |||||||
| Mechanism | Anion exchange resin/polymer | Binds to anion exchange resin/polymer | |||||||
| Key Mechanism Factor 1 | |||||||||
| Factor Name | Chelation | ||||||||
| Factor Description | Chelation is a direct drug interaction that usually involves the formation of dimers or trimers, resulting in larger complexes and poorer absorption. | ||||||||
| Mechanism Description |
|
||||||||
| Recommended Action | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Management | If concomitant use is required, venetoclax should be administered at least 4 to 6 hours after the bile acid sequestrant. Close clinical and laboratory monitoring may be considered during coadministration, since adjusting the dosing interval may not completely prevent the interaction. | ||||||||
| References | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Cerner Multum, Inc. "UK Summary of Product Characteristics.". | ||||||||||||||||||

